시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 부신경절종 시장 보고서(2025년)
Paraganglioma Global Market Report 2025
상품코드 : 1720854
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,487,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,376,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,266,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

부신경절종 시장 규모는 향후 수년간 강력한 성장이 예상될 예정입니다. 또한 신흥 시장의 헬스케어 액세스 개선 등에 기인한다고 생각됩니다. 이 기간에 예상되는 주요 동향에는 표적요법의 진전, 방사성의약품의 확대, 면역요법 접근의 대두, 진단에 있어서의 인공지능(AI)의 이용 강화, 저침습 수술기술의 개발 등이 있습니다.

종양학 연구 및 의료에 대한 투자의 확대가 향후 몇 년간의 종양학 연구 및 의료 시장 확대의 원동력이 될 것으로 예측됩니다. 투자 증가는 세계의 암 이환율 상승, 정밀의료 진보, 혁신적인 치료법에 대한 수요 증가, 임상 검사 확대, 정부 및 민간 자금 제공 이니셔티브, 표적 요법 및 면역 요법의 개발에 의해 촉진되고 있습니다. 선택의 강화, 보다 효과적인 약제의 임상 검사에의 자금 제공, 소아암 치료의 인프라 강화, 질환의 생물학적 성질과 진행의 이해를 깊게 하기 위한 혁신적 연구의 촉진 등에 의해 부신경절종의 진보를 지지하고 있습니다. IQVIA는 2023년 세계의 암 의료에 대한 지출이 2022년부터 250억 달러 증가한 2,230억 달러로 증가하고, 2028년에는 4,090억 달러에 이를 것으로 예측하고 있다고 보고했습니다.

부신경절종 시장의 주요 기업은 경구 저산소 유도 인자-2α(HIF-2a) 억제제와 같은 고급 치료의 개발을 선호하고 환자에게 표적 치료 옵션을 제공합니다. 요인인 HIF-2a 활성을 저해하는 표적 치료이며, 이로써 부신경절종과 같은 상태에서의 암의 진행을 지연시킵니다. 2025년 1월, 미국에 본사를 둔 바이오 제약 회사인 머크는 미국 정부 기관인 미국 식품의약국(FDA)으로부터 웰리렉(벨주티판)에 대한 추가 신약 신청이 우선 검토를 받았다고 발표했습니다. 웰리렉은 진행성, 절제 불가능성 또는 전이성 갈색세포종과 부교세포종(PPGL)을 가진 성인 및 소아 환자(12세 이상)를 대상으로 합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

SHW
영문 목차

영문목차

Paraganglioma is a rare neuroendocrine tumor that arises from paraganglia, clusters of cells associated with the autonomic nervous system. These tumors are typically found in the head, neck, chest, or abdomen and may produce excess hormones, posing a risk of malignancy. Early diagnosis is crucial for effective management and preventing complications.

The main types of paraganglioma include sympathetic, parasympathetic, carotid, cervical, jugular, secretory, and temporal paragangliomas. Sympathetic paragangliomas, which develop in the sympathetic nervous system, often produce catecholamines. These tumors originate from various locations, such as the head and neck, abdomen, pelvis, and other areas. Treatment options include peptide receptor radionuclide therapy, surgery, chemotherapy, radiation therapy, and other approaches. These treatments are distributed through hospital pharmacies, drug stores, retail pharmacies, and online pharmacies, catering to end-users such as hospitals, specialty clinics, and cancer research institutes.

The paraganglioma market research report is one of a series of new reports from The Business Research Company that provides paraganglioma market statistics, including the paraganglioma industry global market size, regional shares, competitors with the paraganglioma market share, detailed paraganglioma market segments, market trends, and opportunities, and any further data you may need to thrive in the paraganglioma industry. This paraganglioma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The paraganglioma market size has grown strongly in recent years. It will grow from $2.89 billion in 2024 to $3.03 billion in 2025 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to advancements in diagnostic imaging, increased awareness and screening programs, regulatory approvals for targeted therapies, the expansion of specialized treatment centers, and progress in genetic testing.

The paraganglioma market size is expected to see strong growth in the next few years. It will grow to $3.64 billion in 2029 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to emerging targeted therapies and immunotherapies, the expansion of radiopharmaceuticals, the rising prevalence of genetic diseases, increasing investments in rare disease research, and improved healthcare access in emerging markets. Major trends expected during this period include advancements in targeted therapies, the expansion of radiopharmaceuticals, the rise of immunotherapy approaches, enhanced use of artificial intelligence (AI) in diagnostics, and the development of minimally invasive surgical techniques.

The growing investments in oncology research and medicine are expected to drive the expansion of the paraganglioma market in the coming years. Investments in oncology research and medicine refer to financial commitments made by governments, pharmaceutical companies, research institutions, and private investors to advance cancer prevention, diagnosis, and treatment. The increase in such investments is fueled by the rising global cancer burden, advancements in precision medicine, growing demand for innovative therapies, expansion of clinical trials, government and private funding initiatives, and the development of targeted and immunotherapy treatments. These investments support advancements in paraganglioma by improving early diagnosis, enhancing treatment options such as targeted therapies and immunotherapy, funding clinical trials for more effective drugs, strengthening pediatric cancer care infrastructure, and fostering innovative research to better understand the disease's biology and progression. For instance, in May 2024, IQVIA, an India-based information technology company specializing in advanced analytics, reported that global spending on cancer medicine increased to $223 billion in 2023, a $25 billion rise from 2022, and is projected to reach $409 billion by 2028. As a result, the increasing investments in oncology research and medicine are fueling the growth of the paraganglioma market.

Leading companies in the paraganglioma market are prioritizing the development of advanced therapies such as oral hypoxia-inducible factor-2 alpha (HIF-2a) inhibitors to provide targeted treatment options for patients. An oral HIF-2a inhibitor is a targeted therapy that inhibits HIF-2a activity, a key factor in tumor growth under low-oxygen conditions, thereby slowing cancer progression in conditions such as paraganglioma. For example, in January 2025, Merck, a US-based biopharmaceutical company, announced that its supplemental new drug application for Welireg (belzutifan) received priority review from the U.S. Food and Drug Administration (FDA), a US-based government agency. Welireg is intended for adult and pediatric patients (12 years and older) with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma (PPGL). The supplemental new drug application (sNDA) is supported by objective response rate (ORR) and duration of response (DOR) data from the Phase 2 LITESPARK-015 trial.

In January 2022, Exact Sciences Corp., a US-based molecular diagnostics company, acquired PreventionGenetics for an undisclosed amount. This acquisition was aimed at expanding Exact Sciences' hereditary cancer testing capabilities, increasing access to early detection and personalized treatment options. PreventionGenetics, a US-based clinical genetic testing laboratory, specializes in genetic testing for hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndrome.

Major players in the paraganglioma market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mount Sinai, Penn Medicine, Stanford Health Care, St. Jude Children's Research Hospital, UT Health San Antonio, The University of Chicago Medical Center, Fred Hutchinson Cancer Center, Florida Cancer Specialists & Research Institute, Invitae Corp., Clinigen Group plc, Fulgent Genetics, Dana-Farber Cancer Institute Inc., Oncology Hematology Care Inc., Enterome, National Institutes of Health Clinical Center, Progenics Pharmaceuticals Inc., Pheo Para Alliance, Saint John's Cancer Institute.

North America was the largest region in the paraganglioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in paraganglioma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the paraganglioma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The paraganglioma market consists of revenues earned by entities by providing services such as diagnosis & screening services, post-treatment and support services, and clinical trials and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The paraganglioma market also includes sales of imaging kits, alpha-adrenergic blockers, and supportive care products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Paraganglioma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on paraganglioma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for paraganglioma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The paraganglioma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Paraganglioma Market Characteristics

3. Paraganglioma Market Trends And Strategies

4. Paraganglioma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Paraganglioma Growth Analysis And Strategic Analysis Framework

6. Paraganglioma Market Segmentation

7. Paraganglioma Market Regional And Country Analysis

8. Asia-Pacific Paraganglioma Market

9. China Paraganglioma Market

10. India Paraganglioma Market

11. Japan Paraganglioma Market

12. Australia Paraganglioma Market

13. Indonesia Paraganglioma Market

14. South Korea Paraganglioma Market

15. Western Europe Paraganglioma Market

16. UK Paraganglioma Market

17. Germany Paraganglioma Market

18. France Paraganglioma Market

19. Italy Paraganglioma Market

20. Spain Paraganglioma Market

21. Eastern Europe Paraganglioma Market

22. Russia Paraganglioma Market

23. North America Paraganglioma Market

24. USA Paraganglioma Market

25. Canada Paraganglioma Market

26. South America Paraganglioma Market

27. Brazil Paraganglioma Market

28. Middle East Paraganglioma Market

29. Africa Paraganglioma Market

30. Paraganglioma Market Competitive Landscape And Company Profiles

31. Paraganglioma Market Other Major And Innovative Companies

32. Global Paraganglioma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Paraganglioma Market

34. Recent Developments In The Paraganglioma Market

35. Paraganglioma Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기